CCR5 inhibitors: up and coming new agents.

Abstract

A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamentarium this year.